248 related articles for article (PubMed ID: 22769724)
1. Investigative safety science as a competitive advantage for Pharma.
Moggs J; Moulin P; Pognan F; Brees D; Leonard M; Busch S; Cordier A; Heard DJ; Kammüller M; Merz M; Bouchard P; Chibout SD
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1071-82. PubMed ID: 22769724
[TBL] [Abstract][Full Text] [Related]
2. Drug safety testing paradigm, current progress and future challenges: an overview.
Ahuja V; Sharma S
J Appl Toxicol; 2014 Jun; 34(6):576-94. PubMed ID: 24777877
[TBL] [Abstract][Full Text] [Related]
3. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
Stevens JL
Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
[TBL] [Abstract][Full Text] [Related]
4. Computational science in drug metabolism and toxicology.
Valerio LG
Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):781-4. PubMed ID: 20465524
[TBL] [Abstract][Full Text] [Related]
5. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE
Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
[TBL] [Abstract][Full Text] [Related]
6. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
7. Advances in the development and use of human tissue-based techniques for drug toxicity testing.
Clotworthy M; Archibald K
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1155-69. PubMed ID: 23687950
[TBL] [Abstract][Full Text] [Related]
8. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing.
Pellegatti M
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1171-80. PubMed ID: 23705836
[TBL] [Abstract][Full Text] [Related]
11. Toxicity testing in the 21st century: bringing the vision to life.
Andersen ME; Krewski D
Toxicol Sci; 2009 Feb; 107(2):324-30. PubMed ID: 19074763
[TBL] [Abstract][Full Text] [Related]
12. Computational systems biology and dose-response modeling in relation to new directions in toxicity testing.
Zhang Q; Bhattacharya S; Andersen ME; Conolly RB
J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):253-76. PubMed ID: 20574901
[TBL] [Abstract][Full Text] [Related]
13. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
Morford LL; Bowman CJ; Blanset DL; Bøgh IB; Chellman GJ; Halpern WG; Weinbauer GF; Coogan TP
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):359-80. PubMed ID: 21770023
[TBL] [Abstract][Full Text] [Related]
14. Exploratory drug safety: a discovery strategy to reduce attrition in development.
Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
[TBL] [Abstract][Full Text] [Related]
15. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
16. Optimizing drug discovery by Investigative Toxicology: Current and future trends.
Beilmann M; Boonen H; Czich A; Dear G; Hewitt P; Mow T; Newham P; Oinonen T; Pognan F; Roth A; Valentin JP; Van Goethem F; Weaver RJ; Birk B; Boyer S; Caloni F; Chen AE; Corvi R; Cronin MTD; Daneshian M; Ewart LC; Fitzgerald RE; Hamilton GA; Hartung T; Kangas JD; Kramer NI; Leist M; Marx U; Polak S; Rovida C; Testai E; Van der Water B; Vulto P; Steger-Hartmann T
ALTEX; 2019; 36(2):289-313. PubMed ID: 30570669
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomics for drug toxicity.
Gao Y; Holland RD; Yu LR
Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
[TBL] [Abstract][Full Text] [Related]
18. Safety biomarkers in preclinical development: translational potential.
Sasseville VG; Mansfield KG; Brees DJ
Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
[TBL] [Abstract][Full Text] [Related]
19. Application of genomics in preclinical drug safety evaluation.
Lord PG; Nie A; McMillian M
Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
[TBL] [Abstract][Full Text] [Related]
20. Reducing attrition in drug development: smart loading preclinical safety assessment.
Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
